Eurofins Strengthens Its Global Leadership Position in Cosmetics and Personal Care Products Testing and Clinical Services and Grows Its Position in Dermatology Drug Testing
04 Août 2021 - 7:15AM
Business Wire
Eurofins (Paris:ERF) Cosmetics & Personal Care Testing
Business line is the leading provider in cosmetics suncare and
personal care testing worldwide, offering the most comprehensive
range of testing and clinical services from 26 state-of-the-art
laboratories in Europe, North America, Asia-Pacific and Africa and
unrivalled customer service. Supported by 16 clinical laboratories,
Eurofins Cosmetics & Personal Care testing offers unmatched
clinical capabilities and innovation worldwide.
In line with our strategy to expand our global leadership in
cosmetics and personal care and to diversify our clinical testing
footprint in dermatology, for medicinal products and medical
devices, Eurofins announces that it has successfully completed
acquisition of bioskin GmbH (“bioskin”) a full-service,
dermatology-specific CRO specialising in trials for drugs, medical
devices, food supplements and advanced cosmetics.
Over the last 30 years bioskin has built a reputation for
excellence in providing clinical trials in dermatology for
medicinal products and for medical devices. bioskin employs over 60
staff in its facility in Hamburg and has generated revenues of over
EUR 11m in 2020. bioskin brings to Eurofins innovative
capabilities, a strong position in early phase studies and
proof-of-concept models, international multi-centre phase II–III
studies, and unique expertise with its own in-house research
centre.
This acquisition, providing a range of complementary and
extended services, supports Eurofins’ continued growth plans in
these markets and further strengthens our offering to our customers
and facilitates their one-stop access to multicentric studies.
Eurofins’ CEO, Gilles Martin commented: "Cosmetics suncare and
personal care Products have an impact on our health and well-being.
Manufacturers active in these fast growing industries constantly
innovate to develop better products for consumers and patients. We
are therefore now very excited to partner with bioskin and broaden
and deepen the range of testing and quality of service we can offer
our clients in developing cosmetics, personal care and dermatology
products."
Notes to Editors:
For more information, please visit
www.eurofins.com.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With over 50,000 staff across a
network of more than 800 laboratories in over 50 countries,
Eurofins’ companies offer a portfolio of over 200,000 analytical
methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210803006184/en/
Investor Relations Eurofins Scientific SE +32 2 766 1620
ir@eurofins.com
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024